

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Which of the following statements best characterizes improvements in symptoms reported with nirogacestat for patients with progressing desmoid tumors?
 - a. Symptom improvement occurs concurrently with radiographic response
 - b. Symptom improvement can occur in the first few days or weeks of treatment, before radiographic response occurs
 - c. Symptom improvement occurs several weeks after radiographic response
2. Which of the following statements regarding the safety of nirogacestat is most accurate?
 - a. Fatigue is a chronic adverse event that persists through extended treatment but can be managed with caffeine supplementation
 - b. Mucositis occurs in approximately 30% of patients but can be managed with steroid mouthwash, painkillers and dose reduction
 - c. Nirogacestat is contraindicated for postpartum women
 - d. All of the above statements are equally accurate
3. Which of the following statements best characterizes desmoid tumor responses to nirogacestat reported by size?
 - a. Small tumors elicited the greatest responses
 - b. Large tumors elicited the greatest responses
 - c. Tumor size did not significantly affect response dynamics
4. Which of the following statements is true regarding the clinical activity of nirogacestat in progressive desmoid tumors reported by tumor focality?
 - a. Nirogacestat has been studied in patients with unifocal disease only
 - b. Patients with multifocal disease derive less benefit from nirogacestat and may require additional surgical management
 - c. Nirogacestat is efficacious in both unifocal and multifocal disease